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Abstract Obtaining genetic testing insurance authorizations
for patients is a complex, time-involved process often requir-
ing genetic counselor (GC) and physician involvement. In an
effort to mitigate this complexity and meet the increasing
number of genetic testing insurance authorization requests,
GCs formed a novel partnership with an industrial engineer
(IE) and a patient services associate (PSA) to develop a
streamlined work flow. Eight genetics clinics and five special-
ty clinics at the University of Michigan were surveyed to
obtain benchmarking data. Tasks needed for genetic testing
insurance authorization were outlined and time-saving work
flow changes were introduced including 1) creation of an
Excel password-protected shared database between GCs and
PSAs, used for initiating insurance authorization requests,
tracking and follow-up 2) instituting the PSAs sending GCs
a pre-clinic email noting each patients’ genetic testing insur-
ance coverage 3) inclusion of test medical necessity documen-
tation in the clinic visit summary note instead of writing a
separate insurance letter and 4) PSAs development of a
manual with insurance providers and genetic testing laborato-
ries information. These work flow changes made it more effi-
cient to request and track genetic testing insurance authoriza-
tions for patients, enhanced GCs and PSAs communication,
and reduced tasks done by clinicians.
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Introduction
Advances in genetics and the advent of next generation se-
quencing technologies has resulted in the introduction of many
new genetic tests, test options, and an increase in the number
of genetic testing laboratories (Genetic Testing Registry 2017,
GeneTests 2017). More patients are being offered genetic test-
ing to inform their medical care, but use is limited due to prob-
lems with obtaining insurance coverage of these tests (Capasso
2014; Prince 2015; Secretary’s Advisory Committee on
Genetics, Health and Society 2006; Spoonamore and Johnson
2016). Obtaining insurance coverage is a multi-step, time-
involved process, which often requires genetic counselor
(GC) and physician involvement (Fig. 1), and presents several
challenges.
Insurance coverage of a genetic test, like other medical
tests, generally depends on demonstrated clinical validity
and evidence of clinical utility, along with there being doc-
umentation of medical necessity (Burke 2014; Capasso
2014; Prince 2015; Secretary’s Advisory Committee on
Genetics, Health and Society 2006; Spoonamore and
Johnson 2016). Generally, insurers have a specific list of
criteria that have to be met for genetic testing to be consid-
ered medically necessary and some may even require
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genetic counseling services to make this determination
(Capasso 2014; Latchaw et al. 2010). The newness of
many genetic tests and the fact that many genetic condi-
tions affect small subsets of the population means that
clinical utility and cost-effectiveness data is often limited
or lacking. In addition, few identified genes and their as-
sociated syndromes have established practice guidelines
for testing decisions and medical management (Uhlmann
and Sharp 2012).
Genetic tests can range in price from hundreds to sev-
eral thousand dollars. Ascertaining the cost of genetic
testing and determining what the patient will be billed is
challenging. The list price of a genetic test may not be
readily available at a laboratory’s website for proprietary
reasons and can vary significantly depending on the spe-
cific test, methodology, testing laboratory and whether the
institution, insurer, or patient is billed (Spoonamore and
Johnson 2016; Uhlmann 2009). Negotiated contracts be-
tween institutions and labs and institutions and insurance
companies impact institutional billing and contracts be-
tween labs and insurance companies impact direct insur-
ance billing (Spoonamore and Johnson 2016). What the
patient is billed and ultimately will pay also depends on
institutional Bmark-ups,^ Bbalance-billing^ policies,
whether a sample is being sent to an in-network or out-
of-network laboratory and the patient’s deductibles and
coinsurance (Capasso 2014; Spoonamore and Johnson
2016). Additionally, there are fees for obtaining and ship-
ping the specimen.
Some institutions will not permit direct billing for ge-
netic testing by an outside lab, which can be problematic
for patients if the lab either does not handle insurance
billing or only will handle for in-state patients. If the
institution or insurer cannot be billed by the lab, the pa-
tient has to have the resources to self-pay and then will
need to submit genetic testing expenses to their insurer for
potential reimbursement. For patients who need to set up
payment plans, this may not be an option offered for
genetic testing done by outside laboratories because the
institution would have to cover the cost if the patient does
not pay. There are some labs that offer patient payment
plans for uninsured or underinsured patients who meet
their financial assistance program criteria.
Insurance coverage of genetic testing is highly variable and
depends on the patient’s insurer, the specific plan and test
indication (e.g. diagnostic or predictive) (Capasso 2014;
• Determine if genetic testing is available
• Conduct online search of databases of laboratories offering genetic
testing (e.g. Genetic Testing Registry, GeneTests)
• Review, assess and compare labs' test options, methodologies, costs and 
result times
• Select genetic test and lab
• Provide pre-test counseling and obtain informed consent
• Complete paperwork for genetic testing (at time of clinic visit or after 
insurance authorization is obtained)
• Document medical necessity information in clinic visit summary letter or
separate letter
Clinician's Tasks in Ordering Genetic Testing
• Ascertain patient's insurer and contact information
• Gather & submit required information:
• Patient's birthdate, insurance member/policy number, group number, 
specific diagnosis and ICD codes
• Ordering physician's name and National Provider Identifier (NPI) 
number. Some labs also require tax identification number
• Genetic test information (specific test, CPT codes, list price)
• Lab information (name of lab, contact information, NPI and tax
identification numbers)
• Letter with medical necessity information 
• Completed informed consent form for genetic testing if required by
insurer
Submit Request for Authorization to Insurer
• Track and follow-up on pending requests
• Notify patient of decision
• If denied, follow peer-to-peer review process to appeal
• If approved, complete paperwork, put order in electronic medical record 
system and coordinate sample collection
Track Request and Follow-up
Fig. 1 Steps in ordering genetic testing and obtaining insurance authorization
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Latchaw et al. 2010; Prince 2015; Secretary’s Advisory
Committee on Genetics, Health and Society 2006;
Spoonamore and Johnson 2016; Uhlmann 2009; Wang et al.
2011). Coverage of predictive genetic testing is particularly
variable because individuals are asymptomatic and therefore
testing is not being done to inform management of an active
medical problem (Prince 2015).
In an effort to circumvent these coverage issues, some ge-
netic testing laboratories have expanded their customer ser-
vices offerings to include handling the insurance prior
authorizations/pre-verifications or providing support (e.g. let-
ter templates). Some laboratories will notify patients if their
out-of-pocket payment will exceed a certain amount and /or
have established a set fee or discounted price if the patient
self-pays fully up front for genetic testing.
It is because of all of the above factors that obtaining in-
surance authorization for genetic testing is cumbersome and
often requires genetic counselors’ input and time (Uhlmann
2009). Genetic counselor (GC) and/or physician (MD) exper-
tise is needed to determine if genetic testing is clinically indi-
cated and available, to select the appropriate genetic test and
laboratory, to provide pre-test counseling and obtain informed
consent, and to clinically interpret and communicate results.
Along with these clinical roles, GCs/MDs are addressing
patients’ insurance coverage questions and requesting and
tracking insurance authorizations, which are all tasks that
can be performed by non-clinicians. The scope of GCs/MDs
involvement in these insurance tasks is evident from internal
experiences and from presentations and discussions nationally
with colleagues. Of note, the term Bgenesurance counseling^
was introduced in 2014 and is defined as Bthat portion of a
genetic counseling session, whether intentional or non-inten-
tional, that is devoted to the topic of costs and insurance/3rd
party coverage (particularly for genetic testing)^ (personal
communication Quinn Stein, MS, CGC and Jason Flanagan,
MS, CGC 11/2/16; Brown et al. 2016a, b).
Given the increase in insurance authorization requests for
genetic testing in the University of Michigan (UM) adult ge-
netics clinics (Cancer Genetics, Medical Genetics, and Breast
and Ovarian Cancer Risk Evaluation Clinic), the Department
of Internal Medicine leadership requested a lean evaluation.
The department’s Performance Improvement Team was asked
to examine work flows and determine support staff needs.
The lean approach involves industrial engineer assessment
of work flows to remove inefficiencies from systems and pro-
cesses, as well as employees’ daily work, in order to take
advantage of the resources that are value-added. Industrial
engineers are rooted in the sciences of engineering, the anal-
ysis of systems and the management of people, and are often
tasked with developing improved processes (http://www.
iienet2.org/). At the UM, a lean evaluation encompasses an
industrial engineer’s assessment of work flows while
mentoring and coaching individuals in process improvement.
GCs from the Medical Genetics and Cancer Genetics
Clinics formed a novel partnership with an industrial engineer
(IE) and patient services associate (PSA) with the goal of
developing a streamlined work flow for obtaining genetic test-
ing insurance authorizations, including delegation of tasks
from GCs to PSAs. Based on UM job descriptions
(http://careers.umich.edu), PSAs generally have a high
school diploma or equivalent; an associate’s degree in health
care and/or business field is a desired qualification.
Depending on the PSAs role, patient billing may be a respon-
sibility, which includes obtaining insurance authorizations for
clinic visits.
We describe the results of the lean evaluation, including
benchmarking data of how different UM clinics were handling
the insurance authorization tasks as well as challenges identi-
fied. We share our streamlined work flow, describe how tasks
were delegated, and present the novel shared database we de-
veloped to initiate and track insurance authorization requests.
Methods
This work was an evaluation and assessment initiated for
quality assurance and improvement and therefore exempt
from IRB review. Benchmarking data was collected in 13
UM clinics. Eight were genetics clinics including the Breast
and Ovarian Cancer Risk Evaluation Clinic, Cancer
Genetics, Cardiovascular Genetics, Medical Genetics,
Neurogenetics, Ophthalmology Genetics, Pediatric
Genetics, and Prenatal Genetics. Five additional specialty
clinics were identified by our Specimen Processing
Sendout Lab as clinics ordering a large number of genetic
tests and included Cardiology (Adult, Pediatrics); and
Neurology (Adult, Ataxia, and Neuromuscular).
The major focus of the data collection was current state
mapping of the components and work flow for genetic testing
insurance authorization and ascertaining who was responsible
for each step in this process. This information was obtained
from an online survey, developed by the IE, PSA and GCs
(WRU and VMR) that was emailed to the GC or MD lead for
each clinic, and from the follow-up interviews. Time needed
for insurance authorization tasks was not assessed in this lean
evaluation because there were not well-established work
flows where the work could easily be tracked and timed.
After survey completion, follow-up interviews were joint-
ly conducted by the IE and PSA with the GC or MD leads
from the eight clinics that agreed to participate. The inter-
views explored the survey questions in greater depth. In
addition, the IE observed the Medical Genetics and Cancer
Genetics Clinics’ lead GCs (WRU and VMR) and PSAs
work flows for genetic testing authorization. After obtaining
this benchmarking data, the IE and PSA met with the
Medical Genetics and Cancer Genetics Clinics’ lead GCs
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to brainstorm ways to increase efficiency, decrease redun-
dancy and reassign tasks from GCs to PSAs, and future state
mapping of an Bideal^ work flow.
Results
Benchmarking Data
Data is presented in aggregate (Table 1) to preserve the ano-
nymity of the participating clinics. Some clinics did not an-
swer all of the survey questions. It was clear from the
benchmarking data that there were several tasks associated
with genetic testing insurance authorization and variability
in how the clinics accomplished this work. Most clinics han-
dled genetic testing authorization requests on a case-by-case
basis and did not have well-established work flows. Several of
the tasks needed to initiate, track, and follow-up on authoriza-
tion requests were handled by GCs/MDs and this was
regarded by interviewees as an inefficient use of their time.
Issues with Ordering Genetic Testing
The number of genetic tests ordered in all of the clinics has
increased and therefore more time is being spent handling
genetic testing for patients. Interviewees noted that selecting
a genetic test was a time-involved process. More research and
consideration of different testing options is needed due to the
increasing number of genetic tests available and labs offering
testing. Utilizing different labs also means following different
processes, which vary in time needed.
In all clinics, the specimen for genetic testing is collected
on the day of the clinic visit when the patient has prior autho-
rization for genetic testing. In eight clinics, a specimen is
collected the same day if 1) the lab can hold the specimen
until authorization is obtained or 2) if the patient opts to pro-
ceed without the prior authorization either because their insur-
er will only make a determination after a claim is submitted or
because s/he does not want to wait to have the test done.
When a patient opts to proceed with testing without prior
authorization, the patient is informed that s/he may end up
being responsible for the full cost of the test if coverage is
Table 1 Benchmarking data on
how clinics handle tasks for
genetic testing insurance
authorization
Task Number of clinics/Who is responsible/How handled
Obtain authorization prior to
clinic visit
3 clinics, only for some patients
Determine if genetic testing
can be ordered
GC or MD (7) responsible
• Review insurance information in EMR and/or ask patient about cover-
age (5)
• Ask MA/staff (1)
• Call insurance company (1)
PSA (3) responsible
Documentation of medical
necessity
Write two separate letters (7 clinics)
Write one clinic visit letter with medical necessity information
(3 clinics)
Have patient complete informed
consent form
10 clinics
• 6 at initial visit
Submit insurance authorization
requests
GC (7) responsible
• Fully (n = 4) or partially (n = 3)
• BPartially^ shared with clinic staff/lab
MD (2) responsible
• MD (1) has assistance from MA.
• MD (1) previously had MA
PSA (3) responsible
Patient provided paperwork (1)
Track pending requests and
notify patients of insurer’s
decision
GC fully or partially responsible in all clinics
Handle insurance denials GC or MD in all clinics
• GC fully or partially responsible (8)
GC genetic counselor, MD physician, MA medical assistant, PSA patient services associate, EMR electronic
medical records
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denied. If a specimen is not obtained the day of the clinic visit,
after insurance authorization is obtained, patients will either
return for genetic testing or arrangements will be made for
sample collection locally.
Handling Insurance Authorization Requests and Impact
Interviewees shared that insurance companies seem to have
limited knowledge about the importance of genetic testing and
that many requests for coverage are denied. Multiple inter-
viewees indicated that handling insurance authorization re-
quests and appeals was not a productive use of GC/MD time
and often a lower priority than other competing clinical tasks.
Interviewees noted that this is problematic because delays in
obtaining insurance approval and proceeding with genetic
testing subsequently delays receiving results and is particular-
ly an issue when timely information is needed to make a
decision about patient management.
All interviewees expressed frustration and shared that
the capacity to grow their clinical volume is negatively
impacted by the logistical work involved with genetic
testing insurance authorizations. Interviewees also
shared that their knowledge of insurance requirements/
coverage of genetic testing was limited and expressed
the need for addi t ional support to assis t with
authorizations.
Work FlowChangesMade and Resources Developed
The major changes made by the Medical Genetics and
Cancer Genetics Clinics were the establishment of a
consistent work flow for genetic testing insurance
authorizations, which previously had been handled on
a case-by-case basis, and the redelegation of several
tasks from the GCs to the PSAs. Figure 2 shows our
streamlined work flow and the tasks now done by
PSAs.
Determining whether Genetic Testing is a Covered Benefit
One example of a work flow change and responsibility shift
from the clinician to the PSA is determining whether genetic
testing is a covered benefit. Having this information available
• PSA looks up each patients' type of insurance
• PSA emails GCs list of patients for upcoming clinic noting whether or not 
genetic testing will be covered, needs prior authorization or determination 
will only be made after testing is completed 
Pre-Clinic
• GC/MD determines whether genetic testing is indicated
• GC/MD will inform patient about insurance coverage for genetic testing/ 
need for authorization based on the information in the PSA's email
• Informed consent form for genetic testing is completed if required by
insurer and imaged by clinic staff
• GC enters patient and genetic test information into shared database during
or post clinic 
Clinic
• GC/MD includes in the clinic visit note/letter the genetic testing and 
medical necessity information
• PSA faxes request for genetic testing and clinic visit note/letter to patient's 
insurer
• PSA tracks genetic testing authorization requests and follows-up with 
insurers as indicated on pending authorizations
• PSA enters insurer's decision in database and images decision letter into 
patient's electronic medical record
• PSA notifies GCs by database and email of insurer's decision and provides 
phone number for peer-to-peer review if request is denied
Post-Clinic
Fig. 2 Work flow for requesting insurance authorization for genetic testing initiated after lean evaluation
Genetic Testing Insurance Authorizations 661
during the clinic visit helps to better guide the discussion
about genetic testing and next steps with obtaining insurance
authorization. Every week, the PSA looks up each patient’s
type of insurance to ascertain whether or not genetic testing
will be covered, needs prior authorization or if determination
of coverage will only be made after a claim is submitted. The
PSA sends a pre-clinic email to the GCs listing the names of
patients under each of the coverage options noted above. This
email is printed by the GC and put with the clinic schedule in
the staffroom so that this insurance information is accessible
to all clinicians, which has reduced interruptions during clinic
visits to ascertain this needed information.
Inclusion of Medical Necessity Information in the Clinic
Visit Summary Note
Another time-saving work flow change is the documentation
of medical necessity. The clinic visit summary note contains
the relevant patient family and medical history information
and diagnostic impression. Writing a separate letter of medical
Table 2 Genetic counselors and
patient services associates
shared database
Data fields entered by genetic counselors Comments
Patient name Fixed columna
Appointment date Fixed columna
CPI This is the patient’s medical record number
Physician Drop-down list of physicians’ names
Diagnosis ICD code(s) are obtained from the patient’s clinic visit note
Genetic test name Select from drop-down list of common tests ordered or type in
test name obtained from lab website
Include lab test number/code if provided
CPT code(s) Obtain from lab website or call lab
Cost Obtain from lab website or call lab
Lab Select from drop-down list of common labs used or type in
name of lab
Proceed? Drop-down options:
BYes, Blood sample was drawn at clinic visit^
BYes, Insurance authorization needed^
BNo.^ BNo^ is selected if a patient subsequently declines
genetic testing after learning testing will either be partially or
not covered by their insurance.
The PSA knows to proceed with obtaining insurance
authorization for all patients in the database, except where
outside lab does pre-verification (noted by GC in
BComments^ field).
GC assignedb Drop-down list of genetic counselors’ names
GC actionb Drop-down options:
LM (left message), testing arranged, testing pending, testing
completed, testing declined, other
GC notesb Field used as needed. May be used to indicate if message was
left for patient, date testing was arranged/paperwork sent,
date results were disclosed and follow-up.
Data fields entered by patient services
associates
Comments
Decision Approval or denial
Authorization
number
If test is approved, authorization number is provided.
Authorization
date
Authorization date and effective dates of approval are noted
Comments Used to record date request made to insurer and other
information (e.g. lab is handling pre-verification)
aMakes it easier to know that you are following the right patient across the 17 data fields without having to keep
checking the first column with the patient’s name. The date column is fixed to easily determine when the patient
was seen and whether enough time has passed to follow-up on the authorization request. Patient rows alternate
between white and gray for easier readability
b These data fields appear in the database after the data fields entered by the patient services associates
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necessity for genetic testing was duplicative effort. Therefore,
the documentation of medical necessity is now incorporated
into the clinic visit summary, for example:
BThe patient’s history is consistent with Ehlers-Danlos
syndrome Type IV (vascular type). This condition re-
sults in increased morbidity and mortality. Genetic test-
ing is recommended and results will impact medical
decision-making: COL3A1 gene sequencing with reflex
to deletion/duplication analysis, [name of lab], [CPT
codes], [list price].^
Creation of Password Protected Shared Database
between GCs and PSAs
The most impactful work flow modification was the develop-
ment of a shared database, allowing GCs and PSAs to effi-
ciently communicate about genetic testing insurance authori-
zation requests and status updates (Table 2). This shared Excel
database is stored on a restricted access, password protected
server. The database established a single, dynamic resource
for GCs and PSAs to enter, track, update, and review all ge-
netic testing insurance authorization requests. Patients having
genetic testing performed by laboratories that handle the in-
surance prior authorizations are also included. This means that
all genetic tests ordered by the clinicians can be efficiently
monitored in a single location, facilitating follow-up and cli-
nician cross-coverage. The database is checked weekly and as
indicated by both the PSAs and GCs. Database use has nota-
bly reduced the number of emails and phone calls between
GCs, MDs and PSAs to determine the current status of genetic
testing authorization requests.
After each clinic or even between patients, GCs enter
patient information into the shared database. Drop downs,
when possible, were generated for specific fields which
save data entry time (Table 2). Using Excel’s search func-
tions and entering the test name, it is possible to also save
time by Bcutting and pasting^ genetic test information from
previous requests in the database; however, it is important
to confirm that the information is up-to-date. Searching the
BProceed^ column for BYes^ or the BGC Action^ column
for BTesting Pending^ readily generates the patients who
have testing in progress and the date submitted can be used
to determine if follow-up is needed.
PSAs Contact Insurers to Initiate and Follow-Up on Test
Authorization Requests
The PSA checks the shared database within three work days
after clinic is held, which allows the GCs time to enter genetic
testing insurance authorization requests and for clinic visit
summary letters to be completed and posted in the electronic
medical records. The PSA calls each patient’s insurer to initi-
ate the authorization request (some provide a case reference
number) and faxes the necessary documentation and forms
(described below).
The PSA faxes to the insurer the clinic visit summary letter
(which also serves as the letter of medical necessity) and a
one-page cover sheet (Fig. 3). The PSA is able to
obtain the necessary patient information (e.g. birthdate,
insurance policy number) for the cover sheet from the
LETTER OF MEDICAL NECESSITY
Re: [Name of Patient] DX: 
DOB:   ICD10: 
INSURANCE:  
Contract: Group: 
TO WHOM IT MAY CONCERN: 
This is a letter requesting prior authorization for Genetic Testing. The information is as follows: 
[name of test] using CPT codes [specific codes] at a cost of $. We will be sending the specimen
to the following laboratory:
Name of lab
Address 
Tax ID:      NPI: Phone: Fax:
Enclosed you will also find our clinical notes from [name of patient] last visit. If more 
information is needed, please contact us at [phone number]. 
Please fax any Approvals or Denials to [fax number]. 
Fig. 3 Coversheet faxed to insurer by patient services associates with clinic visit letter to request insurance authorization for genetic testing
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electronic medical records and the diagnosis and genetic
test information from the shared database or clinic visit letter.
The manual, described below, is used to ensure the correct
insurance specific forms and processes are completed.
The PSA is responsible for tracking pending genetic testing
insurance authorization requests. The information faxed for
each patient is kept in a folder, allowing the PSAs to easily
ascertain which insurance requests are pending. The PSAwill
call the insurer if a determination has not been received within
1–2 weeks of submission (timeframe dependent on insurer).
Communication of Insurer’s Decision about Genetic
Testing Authorization
Communication of the genetic testing coverage decision by
the insurer varies and may be conveyed verbally and/or by
letter. Letters received by the PSA are scanned by the PSA
into the patients’ electronic medical records. Sometimes the
insurer will also send a letter directly to the patient and/or
provider. The PSA notifies the GCs about the insurer’s deci-
sion through the database and additionally by email. The
emails sent by the PSA about the insurer’s decision can be
copied and pasted into the patient’s electronic medical record
along with the GCs documentation.
If authorization for genetic testing is approved and a spec-
imen has not been collected, the GC notifies the patient, com-
pletes test request forms, obtains informed consent, and coor-
dinates specimen collection. If the request for test authorization
is denied, the PSAwill send the GC an email with the phone
number for a peer-to-peer review request; for some insurers, a
written request for appeal is required.
The GC/MD contacts the insurer for the peer-to-peer re-
view and if insurance authorization is subsequently denied,
the GC (sometimes the MD) will notify the patient, discuss
next steps (e.g. potentially testing another family member if
indicated) and the follow-up for their medical management.
Patients are given the option to self-pay for genetic testing,
which generally is declined.
PSAs Creation of a Manual with Needed Information
about Insurers and Genetic Testing Laboratories
The PSAs for the Medical Genetics and Cancer Genetics
Clinics created a manual containing key information needed
for genetic testing insurance authorization requests including:
1. Insurance provider information: phone and fax numbers,
1–3 sentences about whether prior authorization is need-
ed, processes, and required forms.
2. Genetic testing laboratories information: address, phone
and fax numbers, tax identification and National Provider
Identifier (NPI) numbers.
3. List of the clinics’ physicians and genetic counselors’
names and their NPI numbers.
The PSAs compiled this information because they recog-
nized the steep learning curve and the extent of information
required to submit a genetic testing insurance authorization
request. It can be time-consuming to go through insurers’
phone trees to ascertain specific numbers to call and/or fax a
request or appeal. Time is saved by having the insurers and
laboratories’ contact information compiled and accessible so
this needed information is not searched for each time the PSA
submits an authorization request.
Work Flow Issues to Address
As part of the Performance Improvement Team evaluation, we
identified additional issues that need to be addressed to im-
prove the workflow for genetic testing:
Informing Patients about Insurance Coverage Issues
with Genetic Testing
We developed an information sheet that is provided to
patients at check-in by clinic staff notifying them that
genetic testing may be discussed during their clinic vis-
it. It notes that insurance authorization for genetic test-
ing takes time, testing may be fully, partially, or not
covered and introduces the PSA (name and phone num-
ber) as a resource for addressing billing questions. This
approach facilitates informing patients that we know in-
surance coverage is a concern and proactively lets pa-
tients know that the PSA, not the GC, is the best re-
source for insurance questions. However, sometimes
provision of this information has created additional pa-
tient worry and questions about insurance issues at the
onset of the session before it has even been determined
if genetic testing is clinically indicated. How, who and
when to inform patients about insurance coverage con-
tinues to be a work flow task to optimize.
Specimen Collection Issues
Amajor issue to address is specimen collection. When genetic
testing is not done at the clinic visit, additional clinician and/or
staff time is needed to contact the patient and coordinate test-
ing logistics. The patient has to take additional time to return
to the clinic or a blood-drawing station. If a patient lives far
away, arrangements need to be made with the patient’s local
physician or a hospital so that the patient does not drive hours
for just a blood draw. It can be time-consuming to coordinate
genetic testing locally since a site/provider needs to be identi-
fied, the testing logistics and overnight shipping requirement
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need to be explained and arranged/kit sent and completed
paperwork needs to be provided to send with the sample.
Oftentimes, given work or school schedules, conflicts with
other medical appointments or travel logistics, patients cannot
have the sample collected within the specified authorization
dates, which results in a second insurance authorization re-
quest to extend these dates. It takes additional time for the
GCs/MDs and PSAs to handle these extension requests and
further delays the time to results.
Some genetic testing laboratories offer a BDNA extract and
hold^ option, allowing for a blood sample to be collected at
the clinic visit and held at the lab until the insurer has rendered
a decision. However, not all labs offer this option and there-
fore, unless the patient is willing to assume potential financial
responsibility for the genetic testing, specimen collection is
deferred until after insurance authorization is obtained.
While the BDNA extract and hold^ option is convenient for
patients, obtaining and sending a sample to the testing lab and
the lab’s DNA extraction incurs fees, unnecessary expenses if
genetic testing is not performed.
Establishing a way to collect and store specimens the day
of the clinic visit would make genetic testing more efficient for
both patients and clinicians. Logistics about storing samples
(and discarding if insurance coverage is denied), fees, and
determining storage location (clinic/institution or the genetic
testing lab) would need to be worked out. Another option to
explore is the use of saliva and buccal swab kits which provide
a convenient and time efficient home alternative to travel for a
blood sample draw. Specimen collection kits could be sent to
the patient by the laboratory after insurance authorization is
obtained. Utilizing these different options may circumvent
some of the logistical issues of specimen collection outlined
above and should be explored.
Communicating that Specimen was Obtained
For patients who have genetic testing done on a different day
than the clinic visit, it is important for patients to notify the
GC/clinic so that tracking and timely communication of re-
sults occurs. Notification of the GC/clinic is especially impor-
tant when the blood draw occurs at an outside facility since,
unless there is an integrated electronic medical record system,
there is no documentation in the patient’s records that a sample
has been drawn for genetic testing. Therefore, the GCs/MDs
will not know that genetic testing was done and results are
available unless notified or a report is received.
Completion of Paperwork for Genetic Testing
Completion of paperwork for genetic testing is an unnecessary
use of clinician time if testing will not be approved. However,
if paperwork is not completed until after insurance authoriza-
tion is obtained, the paperwork will need to be electronically
sent or mailed to the patient. It is not uncommon for a patient
to misplace the paperwork or to forget to bring the paperwork
to the blood draw which requires re-completion of the paper-
work by the GC/MD if a printed copy is not available or
accessible in the electronic medical record.
During a genetics clinic visit, the benefits, risks, and alter-
natives to genetic testing are discussed, however formal doc-
umentation of informed consent bymeans of patient signature,
is not routinely completed unless a patient opts to undergo
genetic testing. If it is known that an insurer requires written
documentation of informed consent to consider a genetic test-
ing authorization request, this process can be completed dur-
ing the clinic visit.When an informed consent document is not
completed and is then required for insurance authorization,
additional time needs to be spent calling the patient to cover
points in the specific informed consent form, sending the form
to the patient to sign, tracking return and forwarding to the
insurer. If the genetic testing lab does not provide an informed
consent document, time needs to be spent by the GC/MD to
either identify or create a form.
Electronic Medical Records Issues
In our electronic medical record system, it currently is not
possible to enter an order for genetic testing and note that
the sample should not be drawn until insurance authorization
is obtained. Therefore, we do not enter the genetic testing
order in the electronic medical record the day the patient is
seen. This averts having the blood sample for genetic testing
obtained and sent at the time other blood work is done, which
would have financial implications for the patient if insurance
authorization is subsequently denied.
Another electronic medical record issue to address is cur-
rently there is not a way to directly link the patient’s imaged
genetic testing paperwork with the order. Therefore, in order
for the genetic testing paperwork to be sent with the specimen,
the patient either needs to have the genetic testing paperwork in
hand when the sample is collected (required if drawn locally)
and/or the blood draw station needs to know to look for the
paperwork in the patient’s electronic medical records imaged
documents/media section (inaccessible outside the institution).
The work flowwould be smoother if the electronic medical
records issues could be resolved so that an order for genetic
testing could be entered at the clinic visit, a notation made that
insurance authorization is pending and a blood sample should
not yet be drawn and the test forms could be imaged and
attached to the electronic order when completed.
Delegation of More Tasks to PSAs/Clinic Staff
There is a significant amount of information needed to initiate
a genetic testing insurance authorization request, as noted in
the fields in our database (Table 2) and the coversheet the PSA
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sends with the clinic visit note (Fig. 3). To continue to reduce
GC’s time, it may be possible to delegate more of the shared
database field entries to the PSAs. Generally, the list price of a
genetic test is not available on the lab’s website for proprietary
reasons and therefore the lab needs to be called, which can be
done by PSAs. Since all of the information needed to make a
genetic testing insurance authorization request is in the clinic
visit letter, potentially the PSAs could be tasked each week
with reviewing letters from all patients seen and entering the
information in the database with the GCs only responsible for
double-checking the entered information.
In addition, ordering genetic testing often requires comple-
tion of multiple forms and potentially the patient’s contact
information and insurance sections could be completed by
the PSA or clinic support staff. For patients who receive in-
surance approval for genetic testing, the PSA and/or clinic
support staff could take on the responsibilities of notifying
patients, sending the testing paperwork, and making arrange-
ments for samples to be obtained and sent.
Discussion
This is the first paper to describe the different tasks and work
flow issues with obtaining insurance authorization for genetic
testing. Through our GC’s novel partnership with an IE and
PSA, we developed a streamlined work flow that standardized
our genetic testing insurance authorization process, eliminated
tasks that were redundant or unnecessary and clearly defined
roles, responsibilities and points of handoff. We successfully de-
creased the time GCs spend in this process and identified tasks
that could be delegated to PSAs. We have comprehensively de-
scribed the components of our work flow to assist other clinics.
Laying out the steps and tasks involved will also help clinicians,
clinic staff, trainees, administrators, insurers, and policy-makers
to understand the cumbersome time-involved process of
obtaining insurance authorization for genetic testing and work
towards both optimizing this process and staffing appropriately.
Our experience demonstrates that genetic testing insur-
ance authorization tasks can be effectively delegated to
PSAs and do not need to be done by clinicians. Delegating
these tasks to PSAs is feasible given their responsibilities
and work they already do to obtain authorizations for clinic
visits. In order for the PSAs to successfully take on the tasks
associated with genetic testing insurance authorizations, es-
tablishment of work flows, much like we have described,
and clear communication and handoffs between PSAs and
clinicians are needed.
The creation of a centralized password restricted database,
accessible to both GCs and PSAs, was a critical step inmaking
it efficient to initiate insurance authorization requests for ge-
netic testing and track the outcomes. The database has enabled
a smooth handoff of responsibility between the PSAs and
GCs, decreasing emails and phone calls. For the PSAs, creat-
ing a manual with needed information about the insurers, ge-
netic testing laboratories and clinicians was an important time-
saving step.
In the National Society of Genetic Counselors (NSGC)
(2016) Strategic Plan 2016–2018, one of the strategic initia-
tives is to BEngage with technology innovators to facilitate the
development of practice tools and resources to support effi-
cient delivery of genetic services.^ We think the development
of our database is an example of technology use that increases
the efficiency of GCs. Another successful technological ap-
proach for handling the insurance benefits process and
informing patients of their out-of-pocket expenses was pre-
sented at the 2016 NSGC Annual Education Conference.
Williams et al. (2016) developed a prospective insurance ben-
efits work queue within the EPIC electronic medical record
system between the genetics clinic, the patient admissions
group and the clinical laboratory (Williams et al. 2016).
While these work flow changes have helped, the reality
remains that an appreciable amount of time is needed to initi-
ate, track, and follow-up on insurance authorization requests
for genetic testing. Time spent on these tasks by clinicians does
not add value to patient care. The time spent addressing insur-
ance coverage issues also detracts from important discussions
clinicians need to have with patients about potential genetic
testing results, limitations and implications. Furthermore, with
all of the tasks to complete in the insurance authorization pro-
cess, workarounds and wait times, it is possible for patients to
inadvertently Bfall through the cracks^ and not have timely
follow-up on authorization requests, testing done or prompt
communication of results.
Genetic testing generally takes several weeks to months to
complete so adding the time needed to obtain an insurance
authorization and subsequently a sample means the patient
could wait additional weeks to learn a result that could impact
their care. Testing delays can also impact relatives’ care since
identification of a familial pathogenic variant is needed to
implement cascade testing of at-risk relatives and subsequent-
ly initiate evaluation and screening if indicated. Notably, some
patients do not proceed with the recommended genetic testing
if it cannot be done the day of the clinic visit, which has
implications for their care and potentially their relatives.
Generally, in other areas of medicine, testing is done or
arranged at the clinic visit and pages of paperwork do not need
to be completed to order or seek authorization for a medical
test. For manymedical tests, support staff in the clinic/doctor’s
office handle billing and insurance authorizations and a clini-
cian is not routinely actively involved in this process. By
default, because of the complexity of genetic testing and the
information needed to determine coverage, the clinicians at
our institution and elsewhere have ended up being responsible
for several tasks in initiating and tracking insurance authori-
zation requests.
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Some of the time investment by clinicians in seeking insur-
ance authorizations for their patients is being alleviated by
those labs that offer pre-verification/pre-authorization services
and contact patients to communicate the outcome of these
requests. Few labs were offering pre-verification/pre-authori-
zation services at the time our lean evaluation was conducted.
Labs provision of these services is potentially a Bgame-
changer^ in reducing the time clinicians spend handling insur-
ance issues but does raise considerations as to whether the
ease of obtaining insurance authorization for patients will in-
fluence lab and test selection by the clinician. Generally, com-
mercial labs may have more resources to offer pre-verifica-
tion/pre-authorization services than academic labs.
There is much work to be done on a national level with
insurers so that ordering and obtaining authorization for ge-
netic tests has a similar process as other medical tests and
patients can have genetic testing done as part of their clinic
visit like other bloodwork. As noted in the Secretary’s
Advisory Committee on Genetics, Health and Society 2006
report (p. 9): BAlthough advances in genetics and genomics
are driving the development of new genetic tests and services,
problems with coverage and reimbursement of current genetic
tests and services are limiting their accessibility and integra-
tion into the health care system.^ In an effort to address insur-
ance coverage issues, the American College of Medical
Genetics and Genomics in 2015 issued a policy statement
about the clinical utility of genetic tests in patient care,
disagreeing with the narrow view held by some payers, and
emphasizing the clinical utility of results for patients, families
and society (American College of Medical Genetics and
Genomics Board of Directors 2015). The use of genetic test-
ing in patient care will continue to increase and therefore it is
critical to address these insurance coverage issues.
Our time needs to be spent in the genetic testing process
where clinician expertise and skills are needed – patient risk
assessment, researching tests to offer and providing pre- and
post-test counseling. In order for clinicians to meet increasing
demands for genetic services and genetic testing, tasks that
can be done by non-clinicians need to be identified and dele-
gated and work flows simplified. The electronic medical re-
cord issues described in our paper need to be addressed and
other ways of integrating insurance and testing tasks electron-
ically should be explored. Above all, nationally policies on
insurance coverage of genetic testing need to be addressed and
the work involved to make requests reduced in order for cli-
nicians to best provide care for patients and facilitate patients
having genetic testing in a timely manner.
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